WSJ : Teva in Advanced Talks to Buy Allergan’s Generic-Drug Unit

Teva in Advanced Talks to Buy Allergan’s Generic-Drug Unit


Is­raeli drug maker Teva Phar­ma­ceu­ti­cal In­dus­tries Ltd. MMTEVAMM is in talks to com­bine with Al­ler­gan MMAGNMM PLC’s big generic-drug busi­ness, ac­cord­ing to peo­ple fa­mil­iar with the mat­ter, in a move that would rep­re­sent a con­tin­u­a­tion of a boom in health­care deal­mak­ing and likely mean the end of Teva’s pur­suit of an­other ac­qui­si­tion.
A deal for the Al­ler­gan busi­ness, val­ued at about $45 bil­lion, could be an­nounced as early as Mon­day, one of the peo­ple said. The Al­ler­gan unit would be spun off and com­bined with Teva, which has a mar­ket value of $60 bil­lion, this per­son said.
Teva has been seek­ing to buy My­lan NV, a deal My­lan has been re­sist­ing as it pur­sues fel­low drug maker Per­rigo Co.